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PHARMACY
Seizure Prophylaxis in Adult Traumatic Brain 
Injury
Dr Faisal Khan, Phr Muhammad Amir,
Traumatic brain Injury (TBI) bears a high risk of seizures due to focal and diffuse 
brain tissue damage. Post traumatic seizure (PTS) can be classified into early 
(within 7 days) and late (after 7 days). Different anticonvulsants are available 
for prophylactic treatment. To ensure evidence based prescribing of seizure 
prophylaxis therapy in Adult Traumatic Brain injury within the surgical intensive 
Care Unit (SICU). Guideline recommends phenytoin as First line therapy and 
levetiracetam as second line therapy for 7 days.   
Early Traumatic Brain Injury for Adult
For Late PTS, neurological consult should be taken 
Reference 
 http://betaportal.aku.edu/GISurgery/Key%20Documents/Policies,%20Procedures,%20Protocols,%20  
 Clinical%20Practice%20Guideline/Guideline%20for%20seizure%20prophylaxis.pdf
Tizanidine and Ciprofloxacin – Serious Drug 
Interaction
Zainab Qadir, In-patient Pharmacist 
A case reported that concomitant use of ciprofloxacin and tizanidine resulted 
in significant bradycardia, hypotension and hypothermia. Ciprofloxacin is 
a moderately potent inhibitor of CYP1A2 where is Tizanidine, is mainly 
metabolized by it. Ciprofloxacin may greatly elevates plasma concentrations of 
tizanidine and dangerously potentiates its hypotensive and sedative effects, at 
least when administered 1 hour before tizanidine.   
References 
	 1.	 Granfors	MT,	Backman	JT,	Neuvonen	M	et	al:	Ciprofloxacin	greatly	increases	concentrations	and		 	
  hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic 
  metabolism. Clin Pharmacol Ther December, 2004; 76(6):598-606.
	 2.	 Momo	K,	Homma	M,	Kohda	Y	et	al:	Drug	interaction	of	tizanidine	and	ciprofloxacin:	case	report.	
  Clin Pharmacol Ther Dec 1, 2006; 80(6):717-719.
Loading Dose:  
Maintenance 
Therapy:
Phenytoin
17mg/kg  ( 15-20mg /kg)
5 mg/kg/day three divide doses 
(normally 1OOmg-three times daily) 
should be commenced within 12 - 24 
hours
Levetiracetam
20mg/kg lV (rounded to 250mg)
1000 twice daily 
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Seasonal Flu and Influenza Vaccine in Healthcare Workers
Hafsah M Ashfaq, Clinical Pharmacist 
Influenza is a respiratory condition caused by influenza A or B viruses. It’s an epidemic illness occur usually in winters. 
Influenza viruses change their antigenicity frequently. That’s why Annual influenza vaccination is recommended to 
prevent flu infections.
High Risk Individuals: 
	 l Children <5 years, but especially <2 years*
	 l Adults ≥65 years of age
 l Women who are pregnant or up to two weeks postpartum
 l Healthcare workers 
 l Individuals at increased risk for severe influenza (e.g., immunocompromised; chronic cardiovascular, 
  pulmonary, or metabolic disease; pregnancy)
* In young children, rates of hospitalization and mortality are greatest among those <6 months of age.
Influenza infection in healthcare workers and patients is common, and the CDC has published detailed guidelines for the 
prevention and control of nosocomial influenza. The American Academy of Pediatrics, American College of Physicians, 
American Public Health Association, Infectious Diseases Society of America, and Society of Healthcare Epidemiology 
of America have all endorsed mandatory influenza vaccination for all health care workers. Influenza vaccination results 
in fewer influenza infections and fewer missed days from work in such individuals.
Vaccination Schedule: Outbreaks of influenza generally occur during the winter months in the northern and southern 
hemispheres (which occur at different times of the year). A single dose of an influenza vaccine should be administered 
annually and should ideally be offered before the onset of influenza activity in the community (by the end of October in 
the northern hemisphere and by April in the southern hemisphere).
Adverse Reactions: The inactivated influenza vaccines are generally well tolerated, with the most common side effect 
being arm soreness at the injection site (in 64 percent of vaccine recipients). In clinical trials, serious adverse events 
have been reported rarely.
Contraindications & Precautions:  Influenza vaccination is contraindicated in patients who had an anaphylaxis reaction 
to an influenza vaccine.
Patients on anti-coagulants e.g. warfarin can safely receive the influenza vaccine. Few steps should be taken to reduce 
the risk of hematoma in such patients, like small-gauge needles when possible and applying firm pressure (without 
rubbing) to the vaccination site for at least two minutes after vaccination. 
Egg allergy component varies with different manufacturing brands.
References:
	 l World Health Organization (WHO): Recommendations for routine immunization (2018)
	 l	 WHO:	Position	paper	on	vaccines	against	influenza	(2012)
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Raised Concerns on Quinolones for Hypoglycemia and Psychiatric 
Adverse Effect
Muhammad Amir, Specialist 
FDA has released safety concerns for all Quinolones, antibacterial drug, for its hypoglycemic and psychiatric adverse 
effect. This concern have also brought changes in these medication product literature.  Research by FDA identified 
association of fluoroquinolones with hypoglycemic coma (56 reports from October 1987 through April 2017, and 11 
additional cases in the medical literature). It is suggested that fluoroquinolones is insulinotropic effect. Six psychiatric 
adverse effects (disturbance in attention, memory impairment, delirium, nervousness, agitation, and disorientation) has 
been affiliated with these drugs. These effect may appear even after the first dose.
References: 
 U.S. Food and Drug Administration (2018, July07). FDA reinforces safety information about serious low blood sugar levels and mental 
	 health	side	effects	with	fluoroquinolone	antibiotics;	requires	label	changes:	Safety	Communication	-	May	Interfere	with	Lab	Tests.	Retrieved	
 from https://www.fda.gov/downloads/Drugs/DrugSafety/UCM612834.pdf 
Rabies Immunization: Recommendations WHO 2018
Bilal Ahmad: Drug Information Pharmacist
Rabies is a viral infection caused by animal attacks, responsible for an estimated 59 000 human mortalities and over 
3.7 million disability-adjusted life years (DALYs) lost every year. Rabies is almost invariably fatal once clinical 
manifestation happens, as a result of acute progressive encephalitis. WHO recommend pre-exposure vaccination to 
peoples prone to rabies infections. RABIES immunization is achieved via Pre-exposure and Post-exposure prophylaxis.
Post-Exposure Prophylaxis (PEP). In PEP both vaccine and immunoglobulin are administered according to the category 
of exposure: Which is classified as;
Category I exposure is touching or feeding animals or licks on intact skin (no exposure). Category II: nibbling of 
uncovered skin, minor scratches or abrasions without bleeding (exposure). Category III: single or multiple bites or 
scratches, contamination with saliva by licking of mucous membrane or broken skin and direct contact with bats (severe 
exposure).
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Animals causing Rabies
CAT
FOX
BAT
MANGOOSE
DOG
HORSE
BUFFALO
BEAR
MULEMONKEY
WOLF
Category I  Category II exposure  Category III exposure
exposure 
Immunologically naïve
(Not immunized
Previously) individuals 
of all age groups
Wash exposed 
skin surface. 
No PEP 
required
Wound washing and immediate 
vaccination:
ID at 2-sites on days 0, 3 and 7   
OR
IM at 1-site on days 0, 3, 7 and 
between day 14-28   
 OR
IM at 2-sites on days 0 and 1-site 
IM on days 7, 21
RIG is not indicated.
Wound washing and 
immediate vaccination
ID at 2-sites on days 0, 3 and 7
OR
IM at 1-site on days 0, 3, 7 and 
between day 14-28
OR
IM at 2-sites on days 0 and 1-site 
IM on days 7, 21
RIG administration is 
recommended.
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
RABIES Immunoglobulin: RIG are injected around the wound once with dosage of equine-RIG 40IU/kg and human-
RIG 20mg/kg as soon as possible after the initiation of PEP and not beyond day 7 after the first dose of vaccine and the 
remainder of the calculated dose of RIG does not need to be injected IM at a distant site, aseptic syringe can be used for 
other patients. Properly administered, RIG neutralizes the virus at the wound site within a few hours.
Pre-Exposure Prophylaxis: Pre-exposure prophylaxis (PrEP) is the administration of several doses of rabies vaccine 
before exposure to Rabies virus. It is highly recommended for individuals or professionals who are at increased risk for 
rabies exposure i,e living in rabies endemic areas.
For immunologically naive individuals WHO Recommend: Intradermal at 2- sites or a 1-site IM vaccine 
administration on days 0 and 7. For In immunocompromised individuals’ a third dose is administered between Day 21 
and 28. Additionally, in the event of an exposure, a complete PEP course, including RIG, is recommended.
Remember: I. Vaccination schedule should be resumed no restarted after the dose is missed. II. Route and vaccine 
product can be changed during the course, if unavoidable. III Intradermal dose is 0.1ml while for IM whole vial is 
administered.  IV. In all age groups ID (Intradermal) is given in deltoid region while IM is given in deltoid region and 
anterolateral area of thigh for <2 years.
References:
 1. https://www.who.int/immunization/policy/position_papers/pp_rabies_summary_2018.pdf
 2. Tarantola A. Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure. Trop Med Infect 
  Dis. 2017; 2, 5. 
 3. WHO Expert Consultation on Rabies, third report: WHO Technical Series Report, Geneva 2018 (in press) ISBN 978-92-4-121021- 8 
Previously immunized 
individuals of all age 
groups
Wash exposed 
skin surfaces
No PEP 
required.
Wound washing and immediate 
vaccination;
ID at 1-site on days 0 and 3;
OR
ID  at 4-sites on day 0;
OR
IM at 1-site on days 0 and 3);
RIG is not indicated.
Wound washing and immediate 
vaccination*:
ID at 1-site on days 0 and 3;
OR
ID  at 4-sites on day 0;
OR
IM at 1-site on days 0 and 3;
RIG is not indicated.
